Brystana G Kaufman1, Shreyansh Shah2, Anne S Hellkamp3, Barbara L Lytle4, Gregg C Fonarow5, Lee H Schwamm6, Eva Lesén7, Jonatan Hedberg8, Amarjeet Tank9, Edmond Fita10, Narinder Bhalla11, Nipun Atreja12, Janet Prvu Bettger13. 1. Margolis Center for Health Policy, Duke University, Durham, NC, USA. Electronic address: Brystana.kaufman@duke.edu. 2. Department of Neurology, Duke University, Durham, NC, USA. Electronic address: Shreyansh.Shah@duke.edu. 3. Duke Clinical Research Institute, Durham, NC, USA. Electronic address: anne.hellkamp@duke.edu. 4. Duke Clinical Research Institute, Durham, NC, USA. Electronic address: Barbara.lytle@duke.edu. 5. Division of Cardiology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: gfonarow@mednet.ucla.edu. 6. MGH, Boston, MA, USA. Electronic address: LSCHWAMM@mgh.harvard.edu. 7. AstraZeneca, Gothenburg, Sweden. Electronic address: eva.lesen@astrazeneca.com. 8. AstraZeneca, Gothenburg, Sweden. Electronic address: jonatan.hedberg@astrazeneca.com. 9. AstraZeneca, Cambridge, UK. Electronic address: Amarjeet.Tank@astrazeneca.com. 10. AstraZeneca, Cambridge, UK. Electronic address: edmond.fita@astrazeneca.com. 11. AstraZeneca, Wilmington, DE, USA. Electronic address: Narinder.Bhalla@astrazeneca.com. 12. AstraZeneca, Wilmington, DE, USA. Electronic address: nipun.atreja@astrazeneca.com. 13. Margolis Center for Health Policy, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA. Electronic address: janet.bettger@duke.edu.
Abstract
BACKGROUND: Limited real-world data are available on outcomes following non-cardioembolic minor ischemic stroke (IS) or high-risk transient ischemic attack (TIA), particularly in the United States (US). We examined outcomes and Medicare payments following any severity IS or TIA as well as the subgroup with minor IS or high-risk TIA. METHODS: Medicare beneficiaries >65 years were identified using US nationwide Get with the Guidelines (GWTG)-Stroke Registry linked to Medicare claims data. The cohort consisted of patients enrolled in Medicare fee-for-service plan, hospitalized with non-cardioembolic IS or TIA between 2011 and 2014, segmenting a subgroup with minor IS (National Institute of Health Stroke Scale [NIHSS] ≤5) or high-risk TIA (ABCD2-score ≥6) compatible with the THALES clinical trial population. Outcomes included functional status at discharge, clinical outcomes (all-cause mortality, ischemic stroke, and hemorrhagic stroke, individually and as a composite), hospitalizations, and population average inpatient Medicare payments following non-cardioembolic IS or TIA. RESULTS: The THALES-compatible cohort included 62,518 patients from 1471 hospitals. At discharge, 37.0% were unable to ambulate without assistance, and 96.2% were prescribed antiplatelet therapy. Cumulative incidences at 30 days, 90 days, and 1 year for the composite outcome were 3.7%, 7.6%, and 17.2% and 2.4%, 4.0%, and 7.3% for subsequent stroke. The mean Medicare payment for the index hospitalization was $7951. The cumulative all-cause inpatient Medicare spending per patient (with or without any subsequent admission) at 30 days and 1 year from discharge was $1451 and $8105, respectively. CONCLUSIONS: The burden of illness for minor IS/high-risk TIA patients indicates an important unmet need. Improved therapeutic options may offer a significant impact on both patient outcomes and Medicare spending.
BACKGROUND: Limited real-world data are available on outcomes following non-cardioembolic minor ischemic stroke (IS) or high-risk transient ischemic attack (TIA), particularly in the United States (US). We examined outcomes and Medicare payments following any severity IS or TIA as well as the subgroup with minor IS or high-risk TIA. METHODS: Medicare beneficiaries >65 years were identified using US nationwide Get with the Guidelines (GWTG)-Stroke Registry linked to Medicare claims data. The cohort consisted of patients enrolled in Medicare fee-for-service plan, hospitalized with non-cardioembolic IS or TIA between 2011 and 2014, segmenting a subgroup with minor IS (National Institute of Health Stroke Scale [NIHSS] ≤5) or high-risk TIA (ABCD2-score ≥6) compatible with the THALES clinical trial population. Outcomes included functional status at discharge, clinical outcomes (all-cause mortality, ischemic stroke, and hemorrhagic stroke, individually and as a composite), hospitalizations, and population average inpatient Medicare payments following non-cardioembolic IS or TIA. RESULTS: The THALES-compatible cohort included 62,518 patients from 1471 hospitals. At discharge, 37.0% were unable to ambulate without assistance, and 96.2% were prescribed antiplatelet therapy. Cumulative incidences at 30 days, 90 days, and 1 year for the composite outcome were 3.7%, 7.6%, and 17.2% and 2.4%, 4.0%, and 7.3% for subsequent stroke. The mean Medicare payment for the index hospitalization was $7951. The cumulative all-cause inpatient Medicare spending per patient (with or without any subsequent admission) at 30 days and 1 year from discharge was $1451 and $8105, respectively. CONCLUSIONS: The burden of illness for minor IS/high-risk TIA patients indicates an important unmet need. Improved therapeutic options may offer a significant impact on both patient outcomes and Medicare spending.
Authors: Ramon Luengo-Fernandez; Linxin Li; Louise Silver; Sergei Gutnikov; Nicola C Beddows; Peter M Rothwell Journal: Stroke Date: 2021-10-28 Impact factor: 7.914
Authors: Elisabetta Patorno; Sebastian Schneeweiss; Mary G George; Xin Tong; Jessica M Franklin; Ajinkya Pawar; Helen Mogun; Lidia M V R Moura; Lee H Schwamm Journal: Stroke Vasc Neurol Date: 2021-11-08
Authors: Christopher G Favilla; Alice F Ford; Ossama Khazaal; Daniel Cristancho; Emily Grodinsky; Judy Dawod; Scott E Kasner Journal: J Am Heart Assoc Date: 2022-06-22 Impact factor: 6.106